Methodology for processing mastectomy and cryopreservation of breast cancer tissue in a resource- poor setting: A pilot study

Okoli, Uzoamaka; Okafor, Michael; Agu, Kenneth A.; Ndubuisi, Augustine C.; Nwigwe, Ifeoma J.; Nna, Emmanuel Okechukwu; Okafor, Okechukwu Charles; Ukekwe, Francis Ikechukwu; Nwagha, Teresa U.; Menkiti, Victor C.; Eze, Charles; Onyekwelu, Kenechukwu Chibuike; Ikekpeazu, Joy E; Anusiem, Chikere; Mbah, Anthony; Chijioke, Chioli Pascal; Udeniya, Iroka J.

doi:10.1016/j.cryobiol.2020.05.006

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This would increase the accessibility of tissue for organoid culture and has the potential to allow many more researchers to participate in studies using these tissues. Similarly, in an attempt to establish organoids from breast cancer tissue from patients in remote or poorly resourced regions, Okoli et al demonstrated that cryopreservation after the processing of the tissue had no detrimental effect on tissue viability [113]. A further development in this area is the use of "in-plate cryopreservation", which can be applied to organoids.…”

Section: Cryopreservationmentioning

confidence: 99%

Patient-Derived Organoids as a Model for Cancer Drug Discovery

Rae

Amato

Braconi

2021

IJMS

View full text Add to dashboard Cite

In the search for the ideal model of tumours, the use of three-dimensional in vitro models is advancing rapidly. These are intended to mimic the in vivo properties of the tumours which affect cancer development, progression and drug sensitivity, and take into account cell–cell interactions, adhesion and invasiveness. Importantly, it is hoped that successful recapitulation of the structure and function of the tissue will predict patient response, permitting the development of personalized therapy in a timely manner applicable to the clinic. Furthermore, the use of co-culture systems will allow the role of the tumour microenvironment and tissue–tissue interactions to be taken into account and should lead to more accurate predictions of tumour development and responses to drugs. In this review, the relative merits and limitations of patient-derived organoids will be discussed compared to other in vitro and ex vivo cancer models. We will focus on their use as models for drug testing and personalized therapy and how these may be improved. Developments in technology will also be considered, including the use of microfluidics, 3D bioprinting, cryopreservation and circulating tumour cell-derived organoids. These have the potential to enhance the consistency, accessibility and availability of these models.

show abstract

Section: Cryopreservationmentioning

confidence: 99%

Patient-Derived Organoids as a Model for Cancer Drug Discovery

Rae

Amato

Braconi

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The most commonly used CPAs are glycerol 2 and dimethyl sulfoxide (DMSO) 3 . Although some papers have reported cryopreservation of multicellular spheroids and tissues using these CPAs with a certain degree of cell viability [4][5][6][7][8] , generally, cryopreservation is inadequate for multicellular systems.…”

mentioning

confidence: 99%

Cryopreservation of tissues by slow-freezing using an emerging zwitterionic cryoprotectant

Ishizaki

Takeuchi

Ishibashi

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Cryopreservation of tissues is a tough challenge. Cryopreservation is categorized into slow-freezing and vitrification, and vitrification has recently been recognized as a suitable method for tissue cryopreservation. On the contrary, some researchers have reported that slow-freezing also has potential for tissue cryopreservation. Although conventional cryoprotectants have been studied well, some novel ones may efficiently cryopreserve tissues via slow-freezing. In this study, we used aqueous solutions of an emerging cryoprotectant, an artificial zwitterion supplemented with a conventional cryoprotectant, dimethyl sulfoxide (DMSO), for cell spheroids. The zwitterion/DMSO aqueous solutions produced a better cryoprotective effect on cell spheroids, which are the smallest units of tissues, compared to that of a commercial cryoprotectant. Cryopreservation with the zwitterion/DMSO solutions not only exhibited better cell recovery but also maintained the functions of the spheroids effectively. The optimized composition of the solution was 10 wt% zwitterion, 15 wt% DMSO, and 75 wt% water. The zwitterion/DMSO solution gave a higher number of living cells for the cryopreservation of mouse tumor tissues than a commercial cryoprotectant. The zwitterion/DMSO solution was also able to cryopreserve human tumor tissue, a patient-derived xenograft.

show abstract

Methodology for processing mastectomy and cryopreservation of breast cancer tissue in a resource- poor setting: A pilot study

Cited by 2 publications

References 23 publications

Patient-Derived Organoids as a Model for Cancer Drug Discovery

Patient-Derived Organoids as a Model for Cancer Drug Discovery

Cryopreservation of tissues by slow-freezing using an emerging zwitterionic cryoprotectant

Contact Info

Product

Resources

About